Am Fam Physician. 2005 Jan 15;71(2):250-253.
to the editor: On December 8, 2003, I had the honor of testifying before the U.S. Food and Drug Administration’s (FDA’s) Cardiovascular and Renal Drugs Advisory Committee in Washington, D.C. This adventure started with an editorial I wrote for the May 15, 2002, issue of American Family Physician.1 The third U.S. Preventive Services Task Force (USPSTF) found good evidence that the benefit of low-dose (81 mg) daily aspirin therapy in persons at high risk (10-year risk of at least 6 percent) for coronary heart disease (CHD) outweighs any potential harm.2 The USPSTF recommended that we discuss the benefits and harms of aspirin chemoprophylaxis with our at-risk patients, and this recommendation was subsequently endorsed by the American Heart Association (AHA) and the American Diabetes Association (ADA).
Nearly 18 months later I was contacted by the Bayer Health Care Organization, inviting me to participate in the FDA Advisory Committee meeting. When I asked them why they were contacting me, their reply was that they had read the AFP editorial1 and wanted a family physician to testify on the importance of primary prevention of CHD.
Over-the-counter drug labeling supplies information to consumers so they can safely self-medicate, while professional drug labeling provides advice to health care professionals on the safe and effective use of the drug. Currently, the approved professional labeling regarding cardiovascular indications for aspirin use includes suspected acute myocardial infarction (MI), prevention of recurrent MI, and unstable and chronic stable angina. Based on results of recent studies,3,4 Bayer submitted a Citizen’s Petition requesting the FDA’s approval for expanded cardiovascular indications and labeling for the use of a daily aspirin regimen (75 to 325 mg) in persons at high risk for CHD.
The day-long meeting with the FDA Advisory Committee was inspirational and humbling. Data were presented, analyzed, subanalyzed, and debated. I was part of a group who testified during the Open Public Hearing, which was then followed by a heated discussion by the advisory committee. The debate centered on the risk-benefit ratio of aspirin use. Despite studies totaling nearly 55,000 subjects, women and minorities were under-represented, and it was unclear exactly how many were in a low-risk CHD category compared with a moderate-risk category. While there was a 27 percent decrease in nonfatal MIs, the data were less clear with silent and fatal MIs. Although the committee ultimately voted against approval of the request, the reasons given for their votes were enlightening—many who voted “no” took daily aspirin themselves for prophylaxis! The proceedings from this committee can be found online athttp://www.fda.gov/ohrms/dockets/ac/cder03.html#CardiovascularRenal.
So, where does that leave family physicians? We have three major organizations (USPSTF, AHA, and ADA) recommending low-dose aspirin for primary prevention in persons at moderate to high risk for CHD, while the FDA notes that further studies need to be performed. Because these studies will probably not be performed, we are left to what we do best—talk to our patients. For patients who are at increased risk, we can talk to them about modifying their risk factors while discussing the risks and benefits of low-dose aspirin to arrive at a mutual decision. We then need to keep alert for further studies that may help resolve this dilemma.
REFERENCESshow all references
1. Miser WF. An aspirin a day keeps the MI away (for some). Am Fam Physician. 2002;65:20002003....
2. U. S. Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Am Fam Physician. 2002;65:2107–10.
3. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
4. Eidelman RS, Hebert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163:2006–10.
Send letters to firstname.lastname@example.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680. Include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the AAFP permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
This series is coordinated by Kenny Lin, MD, MPH, Associate Deputy Editor for AFP Online.
Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions